New hope for kids with hepatitis b: interferon trial aims for functional cure

NCT ID NCT07231276

Not yet recruiting Disease control Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a weekly injection of pegylated interferon alfa-2b for 48 weeks can help children and teens (ages 3–17) with chronic hepatitis B achieve a functional cure. The treatment group will be compared to an observation group receiving no drug or standard antivirals. The goal is to see if the drug can clear the virus and improve immune responses, potentially leading to better long-term outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pegylated interferon alfa-2b
What this could lead to: If successful, this could point toward a functional cure for chronic hepatitis B in children and teens, reducing their lifelong infection risk.
What could go wrong: This is a phase 4 study with only 113 participants, so results may not apply to everyone. Interferon can cause flu-like symptoms and other side effects, and a functional cure is not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B VIRUS HBV

Contacts and locations

Locations

Nanfang Hospital

Guangzhou, Guangdong, 510515, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.